| Targeting AML through DR4 with a novel variant of rhTRAIL. | |
| | |
MedLine Citation:
|
PMID: 21070598 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different types of tumours, but AML cells are relatively insensitive to TRAIL-induced apoptosis. Here we show that TRAIL-induced apoptosis in AML cells is predominantly mediated by death receptor 4 (DR4) and not DR5. Therefore, we constructed a variant of TRAIL (rhTRAIL-C3) that is a strong inducer of DR4-mediated apoptosis. TRAIL-C3 demonstrated much stronger pro-apoptotic activity than wild-type (WT) TRAIL in a panel of AML cell lines as well as in primary AML blasts. The higher pro-apoptotic potential was further enhanced when the TRAIL mutant was used in combination with BMS-345541, a selective inhibitor of inhibitor-κB kinases. It illustrates that combination of this TRAIL variant with chemotherapeutics or other targeted agents can kill AML with high efficacy. This may represent a major advantage over the currently used therapies that have serious toxic side effects. The high efficacy of rhTRAIL-C3 containing therapies may enable the use of lower drug doses to reduce the toxic side effects and improve patient outcome. Our findings suggest that the rational design of TRAIL variants that target DR4 potentiate the death-inducing activity of TRAIL and offer a novel therapeutic strategy for the treatment of AML. |
| | |
Authors:
|
Eva Szegezdi; Carlos R Reis; Almer M van der Sloot; Alessandro Natoni; Aoife O'Reilly; Janice Reeve; Robbert H Cool; Michael O'Dwyer; Steven Knapper; Luis Serrano; Wim J Quax; Afshin Samali |
Related Documents
:
|
15511228 - Ifn-gamma enhances trail-induced apoptosis through irf-1. 14959858 - Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in ... 11225998 - Chemotherapy sensitization by rituximab: experimental and clinical evidence. 19429088 - Daidzein overcomes trail-resistance in malignant glioma cells by modulating the express... 9048228 - Classification of chemical allergens according to cytokine secretion profiles of murine... 15788108 - Vitamins a and e: metabolism, roles and transfer to offspring. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of cellular and molecular medicine Volume: 15 ISSN: 1582-4934 ISO Abbreviation: J. Cell. Mol. Med. Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101083777 Medline TA: J Cell Mol Med Country: England |
Other Details:
|
Languages: eng Pagination: 2216-31 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd. |
Affiliation:
|
Department of Biochemistry and the National Centre for Biomedical Engineering Science, National University of Ireland, Galway, Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cau...
Next Document: Mesothelial cell differentiation into osteoblast- and adipocyte-like cells.